Tustin, Calif.-based Canon Medical Systems has inked a deal with New York City-based Cleerly to support the adoption of cardiac CT for the detection of heart disease. The collaboration agreement brings together the latestcardiacCT technologies, designed to automate CT acquisition, with auto-generated reporting based on advanced whole-heart atherosclerosis analysis.
“Cleerly is delighted to announce its partnership with Canon, which will for the first time combine Cleerly’s cutting-edge whole-heart quantification and plaque characterization algorithms with Canon’s industry-leading high-definition CT acquisition and reconstruction technology,” says James Min, MD, Cleerly’s founder and CEO. “This groundbreaking partnership will equip physicians with heretofore unseen levels of precision when treating patients, enabling true prevention at scale.”
The collaboration comes at a pivotal moment. Because of recent scientific developments in cardiac disease management, CT is positioned as a first-line tool in the diagnosis and triage of coronary artery disease. But the complexities of introducing a new imaging service-line, and the challenges of reader variability, have hampered widespread adoption of cardiac CT.
The Canon/Cleerly solution directly addresses these challenges by offering artificial intelligence-enabled whole-heart atherosclerosis evaluation with auto-generated reports supporting consistent and clinically relevant results. Whether customers want to build a new advanced cardiac CT imaging program from the ground up or already have an existing one, this integrated solution is expected to help accelerate and enhance cardiac CT programs, company officials say.
“Once again, Canon has harnessed its strengths and expertise to address pressing healthcare problems, such as heart disease,” says Yuji Hamada, president and CEO, Canon Medical Systems, USA. “This partnership is yet another example of how we find creative solutions to serve our customers and help them deliver the highest levels of care.”